Abstract
Abstract: Objective: To evaluate the clinical value of trastuzumab and chemotherapy in patients with Her2-positive locally advanced breast cancer. Methods: Fifty patients with Her2-positive locally advanced breast cancer admitted to our hospital from March 2017 to March 2018 were randomly selected and divided into control group (conventional chemotherapy) and observation group (conventional chemotherapy + trastuzumab). Results: The total effective rate of the observation group was significantly higher than that of the control group, P < 0.05. There was no significant difference in the incidence of adverse reactions between these two groups. Conclusion: The application of trastuzumab combined with chemotherapy in treating Her2-positive locally advanced breast cancer patients can effectively improve its clinical efficacy and has good safety which is worthy of promotion in clinical applications.
References
Yuan Hongwei. Clinical efficacy of targeted drug trastuzumab combined with chemotherapy in patients with Her2 positive locally advanced breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 86-0 .
Chen Yuxiang, Lu Pei. Efficacy and safety of trastuzumab combined with different chemotherapy regimens in the treatment of human epidermal growth factor receptor-2 positive advanced breast cancer [J]. Journal of Pharmaceutical Forum, 2016(9): 13-15 .
Hui Yanhong. The value and feasibility of trastuzumab in neoadjuvant chemotherapy for patients with Her2 positive breast cancer [J]. Journal of Community Medicine, 2015, 13(6): 27-29.
Chen Wei, Xia Sujian, Li He, et al. Cost-effectiveness analysis of trastuzumab in the treatment of human epidermal growth factor receptor-2 positive early breast cancer patients [J]. Chinese Pharmaceutical Journal, 2017, 52(8) ):696-701.
Zhong Like. Observation of the short-term and long-term effects of trastuzumab combined with docetaxel on Her2 positive breast cancer patients [J]. Journal of Clinical Medicine and Archives, 2017, 4(12): 177.